Post-Cardiac Arrest Monitoring
Explore the role of Transcranial Doppler (TCD) in managing post-cardiac arrest syndrome. Learn how real-time cerebral blood flow monitoring with NeuraSignal’s NG2 aids in neuro-prognostication and preventing secondary brain injury.
NeuraSignal Platform for Emboli Detection
Transcranial Doppler (TCD) ultrasound is the gold standard for the detection of cerebral emboli, providing the only clinically available method to identify microembolic signals in real time as they travel through the cerebral circulation. In addition to emboli detection, TCD enables continuous measurement of cerebral blood flow velocity and pulsatility, allowing for dynamic, beat-to-beat hemodynamic assessment at the bedside. Its portability, repeatability, noninvasive nature, and superior assessment of cerebral blood flow dynamics and emboli detection make it an indispensable modality in critical care and neurovascular monitoring.
Key TCD parameters measured include:
Peak Systolic Velocity (PSV) — velocity at peak cardiac contraction
Mean Flow Velocity (MFV) — average velocity across the cardiac cycle
End-Diastolic Velocity (EDV) — velocity at end of cardiac relaxation
Pulsatility Index (PI) — reflects downstream cerebrovascular resistance
The Challenge
Brain Injury After Cardiac Arrest
Background
Cardiac arrest is a leading cause of mortality and morbidity worldwide, with an incidence rate of up to 86 per 100,000 individuals in Europe alone. 1 Of those who achieve return of spontaneous circulation (ROSC), up to two-thirds may die in the subsequent 24–72 hours due to ongoing cerebral injury, myocardial dysfunction, and a massive systemic inflammatory response. 2 The prognosis of patients who survive to ICU admission depends largely on the severity of neurological injury, making prevention of secondary brain injury the mainstay of post-resuscitation treatment. 3
Every year
adult in-hospital cardiac arrests occur in the U.S.
Only
had a positive neurological outcome at discharge in CARES 2024 data
Why Cerebral Blood Flow Monitoring Matters
After cardiac arrest, multiple overlapping pathophysiological processes contribute to cell death during the post-resuscitation period — including alterations in cerebral blood flow (CBF), raised intracranial pressure, metabolic disorders, imbalanced oxygen delivery, and reperfusion injury. 2 Research has demonstrated a characteristic temporal pattern: an initial period of cerebral hypoperfusion in the first 24 hours after arrest, followed by a hyperemia (hyperperfusion) phase. 4 5 Impaired cerebral blood flow autoregulation (CBFA) is a hallmark of post-cardiac arrest syndrome, and monitoring it is critical for optimizing patient care and prognostication. 6
TCD-Guided Therapy
The GOODYEAR feasibility study explored TCD goal-directed therapy after cardiac arrest, using TCD measurements to optimize cerebral blood flow determinants including mean arterial pressure (MAP) challenges. After optimization, 15% of patients still showed signs of cerebral hypoperfusion, highlighting the value of continuous TCD monitoring in identifying patients who need further intervention. 10
TCD in Pediatric Cardiac Arrest
TCD-based management algorithms have also been explored in pediatric asphyxial out-of-hospital cardiac arrest, where point-of-care TCD ultrasound was used to guide cerebral perfusion optimization — demonstrating the versatility of TCD across patient populations. 11
Clinical Evidence
TCD in Post–Cardiac Arrest Prognostication
A landmark prospective study of 139 patients (the NORCAST sub-study) performed serial TCD examinations at days 1, 3, and 5–7 after out-of-hospital cardiac arrest. The study found that PSV in the middle cerebral artery was low during TTM (Day 1) and elevated after rewarming (Day 3). In patients with good neurological outcomes, PSV normalized thereafter. In patients with poor outcomes, PSV continued to rise. At days 5–7, PSV was 1.0 m/s in good-outcome patients versus 1.3 m/s in poor-outcome patients (p < 0.001). 4 These findings suggest that serial TCD examinations during the first week after cardiac arrest may significantly improve our understanding of serious brain injury and aid in prognostication.
In comatose patients two hours after ROSC, persistence of a diffuse hypodynamic TCD pattern (low mean velocity, high pulsatility) predicts poor neurologic recovery. Conversely, early or late presence of a diffuse hyperdynamic pattern (high mean velocity, low pulsatility) is also associated with poor prognosis, as it may indicate progression toward intracranial hypertension and brain death. 7
Research on cerebral autoregulation has shown that within the first 24 hours after resuscitation, autoregulation is frequently impaired, meaning the brain cannot adequately buffer against fluctuations in blood pressure — making real-time monitoring essential for guiding hemodynamic management. 9
Book a Live Demo
Let's Get started
Discover the future of automated Transcranial Doppler technology. Schedule a brief demo with our specialists to see how non-invasive, robotic TCD fits into your hospital’s workflow.
With real-time information, clinical teams can make more informed decisions about patient management, leading to reduced length of stay and improving patient outcomes.
With the NeuraSignal Platform, healthcare professionals can detect and manage complications more quickly, helping to prevent adverse outcomes, reduce hospital readmissions, and ultimately leading to better patient satisfaction.
References
- Grasner JT, et al. “EuReCa ONE-27 Nations, ONE Europe, ONE Registry.” Resuscitation. 2016;105:188–95. — via Hoedemaekers C. (2022), Springer
- Sinha N, Parnia S. “Monitoring the Brain After Cardiac Arrest: a New Era.” Current Neurology and Neuroscience Reports. 2017;17:62. — Springer
- Hoedemaekers C. “Post-cardiac Arrest Care: Usefulness of Transcranial Doppler (TCD/TCCS) in Cerebral Hemodynamic Monitoring After Resuscitation.” In: Neurosonology in Critical Care. Springer; 2022. pp 731–741. — Springer
- Reichenbach A, et al. “Transcranial Doppler during the first week after cardiac arrest and association with 6-month outcomes.” Frontiers in Neurology. 2023;14:1222401. — Frontiers
- Iordanova B, et al. “Alterations in Cerebral Blood Flow after Resuscitation from Cardiac Arrest.” Frontiers in Pediatrics. 2017;5:174. — Frontiers
- Petrovčič R, Rakusa M, Markota A. “Monitoring of Cerebral Blood Flow Autoregulation after Cardiac Arrest.” Medicina. 2024;60(9):1381. — MDPI / PMC
- Álvarez-Fernández JA. “Transcranial Doppler ultrasound use in post-cardiac arrest coma.” Rev Neurol. 2011;53(9):545-54. — PubMed
- aqvi J, et al. “Transcranial Doppler ultrasound: a review of the physical principles and major applications in critical care.” Int J Vasc Med. 2013;2013:629378. — cited in Sinha & Parnia (2017), Springer
- Sundgreen C, et al. “Autoregulation of Cerebral Blood Flow in Patients Resuscitated From Cardiac Arrest.” Stroke. 2001;32:128–132. — AHA Journals
- “Transcranial Doppler goal-directed therapy after cardiac arrest (GOODYEAR): a feasibility study.” Resuscitation Plus. 2025. — ScienceDirect
- “The Utility of a Point-of-Care Transcranial Doppler Ultrasound Management Algorithm on Outcomes in Pediatric Asphyxial Out-of-Hospital Cardiac Arrest.” Frontiers in Medicine. 2021;8:690405. — Frontiers
Disclaimer of Information & Content
The information provided on the NeuraSignal website is intended for educational and informational purposes only and should not be construed as medical advice, a diagnostic opinion, or a guarantee of clinical outcome. While NeuraSignal strives to present accurate and up-to-date information sourced from peer-reviewed literature and reputable clinical references, NeuraSignal makes no representations or warranties regarding the completeness, accuracy, reliability, or timeliness of any content presented herein. No individual, including patients currently under clinical evaluation, should rely on the information, tools, or resources available on this website for self-diagnosis, self-treatment, or as a substitute for professional medical consultation. Clinical decisions should always be made in partnership with a qualified healthcare provider. NeuraSignal expressly disclaims any liability arising from the use or interpretation of the content on this website.